Coinfection of COVID-19 and viral hepatitis

Abstract

The purpose of this rapid review is to investigate the development of the hepatic manifestations and challenges with SARS-COV-2 and multiple viral hepatitis infections. The literature on the most critical viral, genetic and immunological factors between SARS-CoV-2 and viral hepatitis was reviewed, and the most important interactions that occur with the host were identified in addition to the use of antivirals, another drug, and also the potential of defective viral genomes in antiviral inhibitors. This review specified that some types of viral hepatitis in SARS-COV-2 patients may be reduced reactivation and receive immunosuppressive therapy. We concluded from the current review that it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to persons infected with viral hepatitis. In particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening patient.

Frequency distribution of hepatitis B virus (HBV) genotypes in Iraqi patients

“…Other studies have linked HBV infection with a considerable rise in HBV seropositivity among males and the elderly, in addition to relative genotype distribution. This has been attributed to changes in the infecting genotype as well as mutations in the B-cell and T-cell epitopes in the S-gene of the HBV genome that may contribute to breakthrough infections even among the vaccinated [26][27][28][29][30]. Differences in circulating genotypes, behavioral factors, and host genetic factors, as well as differences in the application of HBV management methods, could explain the differences between our findings and those of the previous study.…”